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health care payer in patients with ﬂuoropyrimidine, irinotecan
and oxaliplatin refractory advanced colorectal cancer.
METHODS: Data on management and resource utilization were
collected using a two round questionnaire send to a representa-
tive expert panel. Patients with 10% and those with 1–10 %
EGFR expressing tumour cells were considered separately as the
latter are theoretically excluded from reimbursement for cetux-
imab, the currently available EGFR directed agent in Belgium.
In the second round, the average, 10 and 90 percentile values of
the responses collected in the ﬁrst round were sent to each expert
who could revise his original answer, acknowledge the average
value or provide a new estimate and rank his answers on a
(un)certainty scale. Costs were obtained by multiplying the
average resource use with the speciﬁc unit cost (ofﬁcial tariffs).
Total costs included costs related to preventive measures, adverse
events, treatment evaluation and symptom control per treatment
cycle (4 or 6 w). RESULTS: Ten different treatment options were
deﬁned by the experts. If EGRF-expressing of the tumour is
10%, Irinotecan-Cetuximab is the treatment of choice in 87%
of patients and responsible for 98% of the total cost of €16,611
(95%CI:€13,271–€20,234). If EGFR-expression of the tumour is
between 1 and 10%, 48% of patients are treated by BSC alone.
BSC is responsible for 18% of the mean overall cost of €6465 per
3 months (95%CI:€4456–€8851) for a patient in this setting.
5FU-MitomycinC is the most used chemotherapy regimen in this
setting (26.04%). CONCLUSIONS: The majority of irinotecan
refractory colorectal cancer patients with a10% EGFR expres-
sion are having further active treatment with irinotecan-
cetuximab responsible for 98% of total costs. In the 1–10 %
EGFR group BSC is the most used treatment option.
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OBJECTIVES: High-risk human papilloma viruses (HPV) can
cause cervical cancer and are associated with high-grade vaginal
and vulvar lesions (especially in younger women). The objective
of the current study was to assess the economic burden of disease
for these lesions in one German hospital. METHODS: Each
patient who received at least one surgical intervention was
included in the analysis. A retrospective analysis from patient
ﬁles was conducted to determine the consumption of resources
and direct medical cost for treatment of 94 women for VIN and
VaIN 2–3 in the Department of Obstetrics and Gynecology at the
University of Düsseldorf, Germany, between 1991 and 2008
analysed retrospectively from the patients’ dossiers. The main
analysis evaluated the costs for surgical interventions and outpa-
tient visits for one year following surgery. RESULTS: A total of
113 surgical interventions (60 in-patient, 53 out-patient) were
performed. 55% of the patients had one intervention and 45%
had more than one interventions. The most frequent interven-
tions were biopsy (77%) and laser vaporisation (72%). There
were 166 out-patient visits with 137 colposcopies, 110 smears
and 60 biopsies. The average direct medical costs were 1355.49€
per patient for in-patient treatment and 208.76 € per patient for
out-patient treatment. The average direct costs for outpatient
visits in the dysplasia clinic were 59.14 € per patient. Adding
indirect costs for sick leave into the main analysis, the average
costs increased to 3451.51 € per patient. CONCLUSIONS: This
analysis provides the ﬁrst estimation of the economic burden of
high-grade vaginal and vulvar lesions in German health care
system. HPV vaccination could prevent half of the high-grade
vaginal and vulvar lesions and could signiﬁcantly reduce the
treatment costs for by these lesions.
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OBJECTIVES: To describe the management of patients with
malignant ascites and to evaluate resource consumption and
associated cost from the hospital provider’s perspective in a pilot
study. METHODS: A cross-sectional, retrospective pilot study
was performed at hospitals of maximum medical care in
Germany. Resource consumption data for e.g. number of para-
centeses, length of hospital stay, diagnostics and drugs were
obtained by patient chart abstraction. Direct medical cost was
calculated. RESULTS: In total, 27 patients with 94 hospital stays
were included in the analysis (mean age 63 years, standard
deviation [SD] 15; 56% male, mean Karnofsky index 54% SD
25). The most common underlying malignancies were gastric
carcinoma (26%), pancreatic carcinoma (15%) and colon car-
cinoma (11%). Mean number of therapeutic paracenteses per
patient was 4.5 (SD 3.8) within the time period from ascites
diagnosis to death. Mean length of hospital stay was 5.5 days
(SD 8.0). Medication mainly comprised human albumin (64%),
diuretics (20%), antibiotics (5%) and cytostatics used for intra-
peritoneal chemotherapy (3%). Mean direct cost per patient and
per hospital stay was €738 (SD1258) and €1011 (SD1584) per
hospital stay with paracentesis as reason for admission. Mean
cost per patient was €2540 (SD 2808). If cost calculation is
based on unit cost for German university hospitals, costs were
18% higher. Main cost driver was the hospital stay (60% of
costs). CONCLUSIONS: Management of malignant ascites
varies with respect to in- or outpatient paracentesis, number of
paracenteses, and concomitant medication. More data are
needed to optimize management and identiﬁcation of cost effec-
tive therapeutic options. In the ﬁeld of palliative care investiga-
tion of resource consumption and costs is challenging since the
needs and quality of life of the patients should always be taken
into consideration.
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OBJECTIVES: To evaluate the treatment cost of IFIs by compar-
ing subjects who developed a proven or probable IFI to matched
controls who did not. METHODS: Data were obtained by ret-
rospective chart review in German hospitals using a non-
randomized parallel group design in patients who have
undergone remission induction chemotherapy for newly diag-
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